Aralez Pharmaceuticals Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2016; Provides Earnings Guidance for the Year Ending December 31, 2017; Reports Impairment Charges for the Fourth Quarter of 2016
For the year, the company reported total revenues, net were USD 54.270 million against USD 21.391 million a year ago. Loss before income taxes was USD 103.042 million against USD 37.609 million a year ago. Net loss was USD 102.978 million against USD 37.783 million a year ago. Diluted loss per common share was USD 1.74 against USD 1.16 a year ago. Loss from operations was USD 102.584 million against USD 37.466 million a year ago. Adjusted EBITDA was USD 46.744 million.
For the year ending December 31, 2017, the company expects net revenues to be in a range of USD 80 million to USD 100 million; and adjusted LBITDA to be in a range of USD 25 million to USD 10 million.
For the fourth quarter, the company reported impairment of intangible assets of USD 4.368 million.